Meeting
2023 ASCO Annual Meeting
Effect of CBM588 in combination with cabozantinib plus nivolumab for patients (pts) with metastatic renal cell carcinoma (mRCC): A randomized clinical trial.
Presenter
Hedyeh Ebrahimi, MD, MPH
City of Hope Comprehensive Cancer Center
Disclaimer
This material on this page is ©2024 American Society of Clinical Oncology, all rights reserved. Licensing available upon request. For more information, please contact licensing@asco.org
Videos & Slides Details
Session Type
Clinical Science Symposium
Session Title
Role of the Microbiome in Immune Checkpoint Inhibitor Response and Resistance
Track
Special Sessions
Sub Track
Kidney Cancer
Clinical Trial Registration Number
NCT05122546
Citation
J Clin Oncol 41, 2023 (suppl 17; abstr LBA104)
DOI
10.1200/JCO.2023.41.17_suppl.LBA104
Abstract #
LBA104
Abstract Disclosures
Similar Videos & Slides
Videos & Slides
2024 ASCO Annual Meeting
Systemic treatments in favorable and very favorable risk metastatic renal cell carcinoma (mRCC): Real world evidence from the International mRCC Database Consortium (IMDC).
Speaker: Martin Zarba, MD, MSc
Videos & Slides
2024 ASCO Annual Meeting
How Cultivating a Sense of Mystery Can Deepen Meaning in Medicine
Speaker: John Jay Wellons, MD, MSPH
Speaker: Angela DeMichele, MD, MSCE, FASCO
Videos & Slides
2024 ASCO Annual Meeting
Electronic patient-reported outcome measures (E-Proms): Results of the H2020 CAPABLE project for patients with metastatic renal cell cancer (mRCC).
Speaker: Laura D Locati